U.S. Parathyroid Disorders Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Parathyroid Disorders Market
- ✓Market Size 2024: USD 1.42 billion
- ✓Market Size 2032: USD 2.26 billion
- ✓CAGR: 6.0%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock Ambulatory Surgery Contracts: Medical device and diagnostics suppliers should secure intraoperative PTH assay and nerve-monitoring contracts with ambulatory surgical centers before the end of 2026, because outpatient parathyroidectomy volume is migrating from hospital operating rooms to lower-cost sites where procurement is consolidating.
Competitive Overview of Parathyroid Disorders in the U.S.
The U.S. parathyroid disorders market is moderately concentrated in branded therapeutics and highly fragmented in diagnostics and surgery. Amgen leads calcimimetics through Sensipar and Parsabiv, while Ascendis Pharma and AstraZeneca compete for the rare hypoparathyroidism niche following AstraZeneca's acquisition of Amolyt Pharma. Generic cinacalcet from Teva Pharmaceuticals and Viatris has compressed prices materially since patent expiry, reshaping margins across the category.
Domestic companies hold structural advantages because purchasing decisions run through U.S. reimbursement channels. Competitive advantage depends on access to Medicare Part D and ESRD bundled payment formularies, relationships with nephrology groups and endocrine surgery centers, and the capacity to fund orphan-drug clinical programs. International entrants without U.S. medical affairs infrastructure face long adoption cycles, so most share gains accrue to companies already embedded in dialysis and endocrinology prescribing networks.
Demand Drivers Shaping Parathyroid Disorder Care in the U.S.
The first driver is the expanding end-stage renal disease population, which the United States Renal Data System reports above 800,000 patients receiving dialysis. Secondary hyperparathyroidism affects most of this cohort, so calcimimetic and active vitamin D volumes scale with dialysis census. Amgen benefits most through Parsabiv, while Teva Pharmaceuticals and Viatris capture volume in generic cinacalcet through formulary substitution by dialysis organizations.
The second driver is rising detection of primary hyperparathyroidism in adults over 60, fueled by routine calcium panels ordered in primary care. Surgical parathyroidectomy and minimally invasive procedures expand accordingly, favoring Medtronic and Stryker, whose intraoperative monitoring tools support focused exploration. The third driver is the approval of long-acting parathyroid hormone replacement, specifically Ascendis Pharma's Yorvipath, which shifts competition toward dosing durability and patient quality-of-life outcomes.
Competitive Restraints and Market Challenges
Price competition is the most immediate constraint. Generic cinacalcet from Teva Pharmaceuticals and Viatris has driven net prices down sharply since patent expiry, forcing Amgen to defend Sensipar through contracting and dialysis bundle positioning rather than list price. Medicare drug price negotiation under the Inflation Reduction Act adds further pressure on branded calcimimetics. Diagnostic laboratories face similar margin compression as Abbott, Roche Diagnostics and Siemens Healthineers bundle intact PTH assays into broader immunoassay contracts.
Talent and infrastructure gaps limit competitive reach. Endocrine surgery capacity is concentrated in academic medical centers in the Northeast, Midwest and California, leaving rural patients dependent on referral chains that delay parathyroidectomy. Compliance costs under FDA quality system requirements and CLIA certification raise entry thresholds for smaller diagnostic and device firms, reinforcing the advantage of established suppliers such as Medtronic and Stryker.
Growth Opportunities for Market Players
The most underserved opportunity lies in hypoparathyroidism, where conventional therapy has long required multiple daily calcium and active vitamin D doses. Ascendis Pharma is targeting this gap with Yorvipath, while AstraZeneca is advancing eneboparatide through its Amolyt acquisition to compete for the same patient population. Early entrants with payer contracts for rare-disease coverage will hold share before 2030.
Ambulatory migration creates a second opening. Outpatient parathyroidectomy and focused intraoperative PTH monitoring favor suppliers that bundle assays, disposables and surgeon training, a space where Medtronic, Stryker and Siemens Healthineers can each offer integrated kits. Laboratory operators such as Quest Diagnostics and LabCorp can extend PTH testing into primary care screening programs targeting adults over 60.
Market at a Glance
| Metric | Detail |
|---|---|
| Market Size 2024 | USD 1.42 billion |
| Market Size 2032 | USD 2.26 billion |
| Growth Rate (CAGR) | 6.0% |
| Most Critical Decision Factor | Payer formulary access across dialysis and Medicare Part D |
| Largest Region | Southern United States |
| Competitive Structure | Concentrated in branded therapeutics, fragmented in diagnostics and surgery |
Leading Market Participants
- Amgen
- Ascendis Pharma
- AstraZeneca
- Teva Pharmaceuticals
- Viatris
- Medtronic
- Stryker
- Roche Diagnostics
- Abbott
- Siemens Healthineers
Regulatory and Policy Environment
The FDA governs therapeutic approvals, and the Orphan Drug Act grants seven years of market exclusivity to hypoparathyroidism treatments, which shapes the competitive window for Ascendis Pharma and AstraZeneca. The Hatch-Waxman Act defines generic entry for cinacalcet, while FDA 510(k) clearance governs intraoperative PTH monitoring devices used by Medtronic and Stryker. CLIA certification determines which laboratories can run PTH assays, affecting Abbott, Roche Diagnostics and Siemens Healthineers.
The CMS ESRD Prospective Payment System bundles calcimimetics and vitamin D analogs into dialysis payments, making dialysis organizations the decisive purchasers. Medicare Part D coverage and the Inflation Reduction Act negotiation framework determine net pricing for branded drugs. The Anti-Kickback Statute constrains manufacturer engagement with nephrology and endocrinology prescribers, pushing companies toward compliant medical education and evidence-based promotion.
Competitive Outlook for Parathyroid Disorders in the U.S.
By 2032, the competitive structure will shift toward greater consolidation among dialysis purchasers, with DaVita and Fresenius Medical Care exerting more control over calcimimetic selection. Generic cinacalcet from Teva Pharmaceuticals and Viatris will hold the majority of volume, leaving Amgen to defend Parsabiv on clinical differentiation and bundled contracting terms.
Rare-disease competition will intensify as Ascendis Pharma and AstraZeneca establish branded hypoparathyroidism franchises. Surgical and diagnostic segments will remain fragmented, but suppliers offering integrated intraoperative monitoring and assay platforms will consolidate share among Medtronic, Stryker, Abbott and Siemens Healthineers.
Frequently Asked Questions
Market Segmentation
- Hypoparathyroidism
- Primary Hyperparathyroidism
- Secondary Hyperparathyroidism
- Tertiary Hyperparathyroidism
- Calcimimetics
- PTH Analogs
- Active Vitamin D Analogs
- Parathyroidectomy Procedures
- Dialysis Organizations
- Hospitals
- Endocrinology Clinics
- Ambulatory Surgical Centers
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.